BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Matoba K, Iizuka N, Gondo T, Ishihara T, Yamada-Okabe H, Tamesa T, Takemoto N, Hashimoto K, Sakamoto K, Miyamoto T. Tumor HLA-DR expression linked to early intrahepatic recurrence of hepatocellular carcinoma. Int J Cancer. 2005;115:231-240. [PMID: 15688398 DOI: 10.1002/ijc.20860] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Liu Z, Noh HS, Chen J, Kim JH, Falo LD Jr, You Z. Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells. J Immunol 2008;181:4363-70. [PMID: 18768895 DOI: 10.4049/jimmunol.181.6.4363] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
2 Jo YS, Lee JC, Li S, Choi Y, Bai Y, Kim Y, Lee I, Rha SY, Ro H, Kim J, Shong M. Significance of the expression of major histocompatibility complex class II antigen, HLA-DR and -DQ, with recurrence of papillary thyroid cancer. Int J Cancer 2008;122:785-90. [DOI: 10.1002/ijc.23167] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
3 Ferrone S, Campoli M. A fresh look at an old story: revisiting HLA class II antigen expression by melanoma cells. Expert Review of Dermatology 2014;1:805-23. [DOI: 10.1586/17469872.1.6.805] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Tokuhisa Y, Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, Tamatsukuri S, Ishitsuka H, Uchida K, Terai S, Sakamoto K, Tamesa T, Oka M. Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma. Br J Cancer 2007;97:1399-403. [PMID: 17940509 DOI: 10.1038/sj.bjc.6604034] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 3.6] [Reference Citation Analysis]
5 Fehlker M, Huska MR, Jöns T, Andrade-Navarro MA, Kemmner W. Concerted down-regulation of immune-system related genes predicts metastasis in colorectal carcinoma. BMC Cancer 2014;14:64. [PMID: 24495478 DOI: 10.1186/1471-2407-14-64] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
6 Matkowskyj KA, Rao MS, Yang GY. Pathologic Features of Primary and Metastatic Hepatic Malignancies. Cancer Treat Res 2016;168:257-93. [PMID: 29206377 DOI: 10.1007/978-3-319-34244-3_13] [Reference Citation Analysis]
7 Midorikawa Y, Makuuchi M, Tang W, Aburatani H. Microarray-based analysis for hepatocellular carcinoma: From gene expression profiling to new challenges. World J Gastroenterol 2007; 13(10): 1487-1492 [PMID: 17461438 DOI: 10.3748/wjg.v13.i10.1487] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
8 Hu B, Yang XB, Sang XT. Construction of a lipid metabolism-related and immune-associated prognostic signature for hepatocellular carcinoma. Cancer Med 2020;9:7646-62. [PMID: 32813933 DOI: 10.1002/cam4.3353] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
9 Iizuka N, Hamamoto Y, Oka M. Prediction of cancer outcome with microarrays. The Lancet 2005;365:1683-4. [DOI: 10.1016/s0140-6736(05)66538-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Gialitakis M, Kretsovali A, Spilianakis C, Kravariti L, Mages J, Hoffmann R, Hatzopoulos AK, Papamatheakis J. Coordinated changes of histone modifications and HDAC mobilization regulate the induction of MHC class II genes by Trichostatin A. Nucleic Acids Res 2006;34:765-72. [PMID: 16452299 DOI: 10.1093/nar/gkj462] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 2.8] [Reference Citation Analysis]
11 Loose D, Van de Wiele C. The immune system and cancer. Cancer Biother Radiopharm. 2009;24:369-376. [PMID: 19538060 DOI: 10.1089/cbr.2008.0593] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
12 Koch KS, Leffert HL. Hypothesis: Targeted Ikkβ deletion upregulates MIF signaling responsiveness and MHC class II expression in mouse hepatocytes. Hepat Med 2010;2010:39-47. [PMID: 23997575 DOI: 10.2147/HMER.S7208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
13 Iizuka N, Tsunedomi R, Tamesa T, Okada T, Sakamoto K, Hamaguchi T, Yamada-okabe H, Miyamoto T, Uchimura S, Hamamoto Y, Oka M. Involvement of c-myc-regulated genes in hepatocellular carcinoma related to genotype-C hepatitis B virus. J Cancer Res Clin Oncol 2006;132:473-81. [DOI: 10.1007/s00432-006-0094-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
14 Shi Y, Zhai W, Wang B, Zhao D, Jin H, Wang Y, Zhang J, An H, Fu Z, Zhao K, Lu C. Genetic susceptibility of eight nonsynonymous polymorphisms in HLA-DRB1 gene to hepatocellular carcinoma in Han Chinese. Oncotarget 2016;7:80935-42. [PMID: 27821814 DOI: 10.18632/oncotarget.13111] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
15 Donson AM, Birks DK, Barton VN, Wei Q, Kleinschmidt-demasters BK, Handler MH, Waziri AE, Wang M, Foreman NK. Immune Gene and Cell Enrichment Is Associated with a Good Prognosis in Ependymoma. J Immunol 2009;183:7428-40. [DOI: 10.4049/jimmunol.0902811] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
16 Midorikawa Y, Sugiyama Y, Aburatani H. Screening of liver-targeted drugs. Expert Opinion on Drug Discovery 2008;3:643-54. [DOI: 10.1517/17460441.3.6.643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
17 Näsman A, Andersson E, Marklund L, Tertipis N, Hammarstedt-Nordenvall L, Attner P, Nyberg T, Masucci GV, Munck-Wikland E, Ramqvist T, Dalianis T. HLA class I and II expression in oropharyngeal squamous cell carcinoma in relation to tumor HPV status and clinical outcome. PLoS One 2013;8:e77025. [PMID: 24130830 DOI: 10.1371/journal.pone.0077025] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 5.8] [Reference Citation Analysis]
18 Tsutsui M, Iizuka N, Moribe T, Miura T, Kimura N, Tamatsukuri S, Ishitsuka H, Fujita Y, Hamamoto Y, Tsunedomi R. Methylated cyclin D2 gene circulating in the blood as a prognosis predictor of hepatocellular carcinoma. Clin Chim Acta. 2010;411:516-520. [PMID: 20064498 DOI: 10.1016/j.cca.2010.01.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
19 Wu XL, Li ZY, Bi XY, Zhao H, Zhao JJ, Zhou JG, Han Y, Huang Z, Zhang YF, Cai JQ. Human leukocyte antigen gene polymorphisms are associated with systemic inflammation in hepatitis B virus-related hepatocellular carcinoma. Cancer Manag Res 2018;10:2315-24. [PMID: 30104900 DOI: 10.2147/CMAR.S167574] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Alisa A, Boswell S, Pathan AA, Ayaru L, Williams R, Behboudi S. Human CD4 + T Cells Recognize an Epitope within α-Fetoprotein Sequence and Develop into TGF-β-Producing CD4 + T Cells. J Immunol 2008;180:5109-17. [DOI: 10.4049/jimmunol.180.7.5109] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
21 Chen P, Zhao L, Wang H, Zhang L, Zhang W, Zhu J, Yu J, Zhao S, Li W, Sun C, Wu C, He Y, Zhou C. Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I-III small cell lung cancer. J Immunother Cancer 2021;9:e002554. [PMID: 34362829 DOI: 10.1136/jitc-2021-002554] [Reference Citation Analysis]
22 Huang YS, Dai Y, Yu XF, Bao SY, Yin YB, Tang M, Hu CX. Microarray analysis of microRNA expression in hepatocellular carcinoma and non-tumorous tissues without viral hepatitis. J Gastroenterol Hepatol. 2008;23:87-94. [PMID: 18171346 DOI: 10.1111/j.1440-1746.2007.05223.x] [Cited by in Crossref: 96] [Cited by in F6Publishing: 89] [Article Influence: 6.9] [Reference Citation Analysis]
23 El-Chennawi FA, Auf FA, Metwally SS, Mosaad YM, El-Wahab MA, Tawhid ZE. HLA-class II alleles in Egyptian patients with hepatocellular carcinoma. Immunol Invest. 2008;37:661-674. [PMID: 18821214 DOI: 10.1080/08820130802111605] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 1.1] [Reference Citation Analysis]
24 Assudani DP, Horton RBV, Mathieu MG, Mcardle SEB, Rees RC. The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines. Cancer Immunol Immunother 2006;56:70-80. [DOI: 10.1007/s00262-006-0154-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
25 Leite FA, Lira RCP, Fedatto PF, Antonini SRR, Martinelli CE, de Castro M, Neder L, Ramalho LNZ, Tucci S, Mastelaro MJ, Seidinger AL, Cardinalli IA, Yunes JA, Brandalise SR, Tone LG, Scrideli CA. Low expression of HLA-DRA, HLA-DPA1 , and HLA-DPB1 is associated with poor prognosis in pediatric adrenocortical tumors (ACT): HLA Class II in Pediatric Adrenocortical Tumors. Pediatr Blood Cancer 2014;61:1940-8. [DOI: 10.1002/pbc.25118] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
26 Iizuka N, Hamamoto Y, Tsunedomi R, Oka M. Translational microarray systems for outcome prediction of hepatocellular carcinoma. Cancer Science 2008;99:659-65. [DOI: 10.1111/j.1349-7006.2008.00751.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
27 Kamdi AS, Kandavalli NB, Emusu D, Jain N, Mamtani M, Porterfield JR. Weak or absent evidence for the association of HLA-DR antigens with risk of thyroid carcinoma: a meta-analysis of observational studies. Tissue Antigens 2011;78:382-9. [DOI: 10.1111/j.1399-0039.2011.01754.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
28 Li C, Bi X, Huang Y, Zhao J, Li Z, Zhou J, Zhang M, Huang Z, Zhao H, Cai J. Variants identified by hepatocellular carcinoma and chronic hepatitis B virus infection susceptibility GWAS associated with survival in HBV-related hepatocellular carcinoma. PLoS One 2014;9:e101586. [PMID: 24987808 DOI: 10.1371/journal.pone.0101586] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
29 Ayaru L, Pereira SP, Alisa A, Pathan AA, Williams R, Davidson B, Burroughs AK, Meyer T, Behboudi S. Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. J Immunol. 2007;178:1914-1922. [PMID: 17237442 DOI: 10.4049/jimmunol.178.3.1914] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 5.7] [Reference Citation Analysis]
30 Lasham A, Print C, Woolley A, Dunn S, Braithwaite A. YB-1: oncoprotein, prognostic marker and therapeutic target? Biochemical Journal 2013;449:11-23. [DOI: 10.1042/bj20121323] [Cited by in Crossref: 133] [Cited by in F6Publishing: 79] [Article Influence: 13.3] [Reference Citation Analysis]
31 Xue F, Higgs BW, Huang J, Morehouse C, Zhu W, Yao X, Brohawn P, Xiao Z, Sebastian Y, Liu Z, Xia Y, Shen D, Kuziora M, Dong Z, Han H, Gu Y, Gu J, Xia Q, Yao Y. HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma. J Transl Med 2015;13:379. [PMID: 26653219 DOI: 10.1186/s12967-015-0743-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
32 Deng Y, Li P, Liu W, Pu R, Yang F, Song J, Yin J, Han X, Li C, Zhao J, Wang H, Cao G. The genetic polymorphism down-regulating HLA-DRB1 enhancer activity facilitates HBV persistence, evolution and hepatocarcinogenesis in the Chinese Han population. J Viral Hepat 2020;27:1150-61. [PMID: 32568442 DOI: 10.1111/jvh.13353] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Sun Y, Li W, Shen S, Yang X, Lu B, Zhang X, Lu P, Shen Y, Ji J. Loss of alanine-glyoxylate and serine-pyruvate aminotransferase expression accelerated the progression of hepatocellular carcinoma and predicted poor prognosis. J Transl Med 2019;17:390. [PMID: 31771612 DOI: 10.1186/s12967-019-02138-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
34 Kim MK, Breitbach CJ, Moon A, Heo J, Lee YK, Cho M, Lee JW, Kim SG, Kang DH, Bell JC. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci Transl Med. 2013;5:185ra63. [PMID: 23677592 DOI: 10.1126/scitranslmed.3005361] [Cited by in Crossref: 53] [Cited by in F6Publishing: 66] [Article Influence: 6.6] [Reference Citation Analysis]
35 Jiang M, Li M, Fu X, Huang Y, Qian H, Sun R, Mao Y, Xie Y, Li Y. Simultaneously detection of genomic and expression alterations in prostate cancer using cDNA microarray. Prostate 2008;68:1496-509. [PMID: 18366025 DOI: 10.1002/pros.20756] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
36 Maass T, Sfakianakis I, Staib F, Krupp M, Galle PR, Teufel A. Microarray-based gene expression analysis of hepatocellular carcinoma. Curr Genomics. 2010;11:261-268. [PMID: 21119890 DOI: 10.2174/138920210791233063] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
37 Mastoraki A, Schizas D, Charalampakis N, Naar L, Ioannidi M, Tsilimigras D, Sotiropoulou M, Moris D, Vassiliu P, Felekouras E. Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma. Mol Diagn Ther 2020;24:175-84. [PMID: 32125662 DOI: 10.1007/s40291-020-00454-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
38 Balhorn R, Balhorn MC, Balakrishnan K, Rebhun RB. The small molecule antibody mimic SH7139 targets a family of HLA-DRs expressed by B-cell lymphomas and other solid cancers. J Drug Target 2020;28:1124-36. [PMID: 32588667 DOI: 10.1080/1061186X.2020.1787418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Chamuleau ME, Ossenkoppele GJ, van de Loosdrecht AA. MHC class II molecules in tumour immunology: prognostic marker and target for immune modulation. Immunobiology 2006;211:619-25. [PMID: 16920500 DOI: 10.1016/j.imbio.2006.05.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
40 Balhorn R, Balhorn MC. Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers. Oncotarget 2020;11:3315-49. [PMID: 32934776 DOI: 10.18632/oncotarget.27709] [Reference Citation Analysis]